Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.
Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:
(12) Patent: | (11) CA 2194576 |
---|---|
(54) English Title: | LONG-ACTING OXYTETRACYCLINE COMPOSITION |
(54) French Title: | COMPOSITIONS A BASE D'OXYTRETRACYCLINE A ACTION PROLONGEE |
Status: | Term Expired - Post Grant Beyond Limit |
(51) International Patent Classification (IPC): |
|
---|---|
(72) Inventors : |
|
(73) Owners : |
|
(71) Applicants : |
|
(74) Agent: | OYEN WIGGS GREEN & MUTALA LLP |
(74) Associate agent: | |
(45) Issued: | 2006-09-12 |
(86) PCT Filing Date: | 1995-07-05 |
(87) Open to Public Inspection: | 1996-01-25 |
Examination requested: | 2002-02-08 |
Availability of licence: | N/A |
Dedicated to the Public: | N/A |
(25) Language of filing: | English |
Patent Cooperation Treaty (PCT): | Yes |
---|---|
(86) PCT Filing Number: | PCT/GB1995/001583 |
(87) International Publication Number: | GB1995001583 |
(85) National Entry: | 1997-01-07 |
(30) Application Priority Data: | ||||||
---|---|---|---|---|---|---|
|
An injectable composition of higher residual effect with reduced detrimental
effects such as pain at injection site, swelling, tissue
irritancy or necrosis and containing as active principle a tetracycline
compound, either as the free base or a salt thereof with a physiologically
acceptable acid, complexed with a substantially equimolar amount of a
magnesium compound, is solubilised in a water miscible solvent
system comprising, either (i) a) glycerol formal in an amount of from about 10
to about 50 % v/v; with b) polyethylene glycol in an amount
of from about 1 to 15 % v/v; or (ii) from about 25 to about 75 % v/v of N-
methylpyrrolidone, said composition optionally containing a pH
modifier in an amount sufficient to maintain a physiochemically acceptable pH,
the balance being made up with water q.s.
Une composition injectable présentant un effet résiduel supérieur avec des effets préjudiciables réduits tels que la douleur sur le site d'injection, le gonflement, l'irritation des tissus ou la nécrose, et contenant comme principe actif un composé de tétracycline, soit comme base libre soit comme sel de celle-ci avec un acide physiologiquement acceptable, transformé en complexe avec une dose sensiblement équimolaire d'un composé de magnésium et solubilisé dans un système de solvants miscibles à l'eau comprenant soit (i) a) du glycérol formal en une quantité comprise entre environ 10 et environ 50 % v/v; avec b) du polyethylène-glycol en une quantité comprise entre environ 1 et 15 % v/v; ou (ii) environ 25 à environ 75 % v/v de N-méthylpyrrolidone, ladite composition contenant facultativement un agent modificateur de pH en une dose suffisante pour maintenir un pH physiochimiquement acceptable, le solde étant constitué d'eau q.s.
Note: Claims are shown in the official language in which they were submitted.
Note: Descriptions are shown in the official language in which they were submitted.
Sorry, the representative drawing for patent document number 2194576 was not found.
2024-08-01:As part of the Next Generation Patents (NGP) transition, the Canadian Patents Database (CPD) now contains a more detailed Event History, which replicates the Event Log of our new back-office solution.
Please note that "Inactive:" events refers to events no longer in use in our new back-office solution.
For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Event History , Maintenance Fee and Payment History should be consulted.
Description | Date |
---|---|
Inactive: Expired (new Act pat) | 2015-07-05 |
Grant by Issuance | 2006-09-12 |
Inactive: Cover page published | 2006-09-11 |
Inactive: Final fee received | 2006-05-26 |
Pre-grant | 2006-05-26 |
Notice of Allowance is Issued | 2006-04-21 |
Letter Sent | 2006-04-21 |
Notice of Allowance is Issued | 2006-04-21 |
Inactive: IPC from MCD | 2006-03-12 |
Inactive: Approved for allowance (AFA) | 2005-11-01 |
Inactive: Application prosecuted on TS as of Log entry date | 2002-03-05 |
Letter Sent | 2002-03-05 |
Inactive: Status info is complete as of Log entry date | 2002-03-05 |
All Requirements for Examination Determined Compliant | 2002-02-08 |
Request for Examination Requirements Determined Compliant | 2002-02-08 |
Amendment Received - Voluntary Amendment | 2002-02-08 |
Application Published (Open to Public Inspection) | 1996-01-25 |
There is no abandonment history.
The last payment was received on 2006-06-21
Note : If the full payment has not been received on or before the date indicated, a further fee may be required which may be one of the following
Patent fees are adjusted on the 1st of January every year. The amounts above are the current amounts if received by December 31 of the current year.
Please refer to the CIPO
Patent Fees
web page to see all current fee amounts.
Note: Records showing the ownership history in alphabetical order.
Current Owners on Record |
---|
NORBROOK LABORATORIES LIMITED |
Past Owners on Record |
---|
ALAN PATTERSON |
DREW HOLMES |